ABOUT DATAMONITOR HEALTHCARE 2
About the CNS pharmaceutical analysis team 2
CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into the CNS market 4
Related reports 5
CHAPTER 2 MARKET DEFINITION 9
Introduction 9
CNS sector sizing 9
Neurology and Psychiatry sector sizing methodologies 10
Pain 10
Geographic coverage 11
CHAPTER 3 BACKGROUND AND OVERVIEW 13
CNS market performance 15
Market comparison using the main CNS ATC1 class 15
ATC N class is the largest in terms of both sales value and sales volume 15
CNS market performance by sector 19
The CNS market totaled $95.48 billion in 2007 20
CNS market performance by region 25
High price points means US market dominates 7MM CNS market value 25
5EU sees greatest value growth over past 4 years 26
CNS disease sector comparison 27
Commercial viability of CNS sectors in 2015 28
Market dynamics of key CNS indications through to 2015 30
Growth to arise from all three key pain disease markets 30
Historical sector dynamics 31
Top-line sector comparisons 31
Brand dominance 33
Company dominance 34
Generic dominance 35
CNS product analysis 38
Leading brand analysis 38
Psychiatric brands take up 6 of the top 10 CNS brand positions 38
Case study analysis 1: versatile drug classes excel in the CNS market 40
N3A - Anticonvulsants 42
N5A - Antipsychotics 44
N6A - Antidepressants 46
Case study analysis 2: promotional spend in the CNS market 49
Promotional spend by region 49
Promotional spend by ATC4 class 50
Promotional spend by brand 52
Leading company involvement in the CNS market 54
Sales performance of the top 10 CNS companies of 2007 54
J&J consolidates its market leading position as its nearest rivals experience a decline in their CNS portfolios 54
Sector presence 56
Market leading company assessment 59
J&J -CNS franchise faces a challenging future following key patent expiries 59
Pfizer - Lyrica lays the groundwork for a new generation of CNS offerings 61
GSK - protecting its neurology portfolio remains the immediate focus 63
Forecast performance of other key CNS companies through to 2012 64
Tactical acquisitions to provide greater CNS market presence for UCB and Schering Plough 65
CHAPTER 4 NEUROLOGY 68
Market dynamics 69
Neurology market size and structure 69
US and EU are key neurology growth regions 69
Key indication market dynamics 70
Commercial viability of key neurological indications in 2015 71
Market dynamics and prevalence through to 2015 73
Historical sales dynamics of key neurological indications over the period 2004-07 75
Company analysis 81
Neurological drugs definition 81
Top five neurological drug companies' comparative marketed and pipeline portfolio potential 82
Historical performance and top-line dynamics of the leading neurological drug companies in 2007 84
Analysis of the top five neurological drug companies of 2007 87
Star performers within the neurological drug market - Emergence of UCB, Forest and Sepracor 98
Brand analysis 100
Anticonvulsants dominate the top 10 selling neurological drug brands 100
Key disease-specific insight 103
Alzheimer's disease 103
Key market insights 103
Market forecast summary 104
Disease definition 105
Epidemiology 106
Current market dynamics 107
Issues affecting the global Alzheimer's disease market 109
Key product launches and patent expiries through to 2016 113
Epilepsy 115
Key market insights 115
Market forecast summary 116
Disease definition 116
Epidemiology 118
Current market dynamics 120
Key companies and leading brands in the epilepsy market 123
Issues affecting the global epilepsy market 127
Key product launches and patent expiries through to 2016 131
Insomnia 133
Key market insights 133
Market forecast summary 134
Disease definition 135
Epidemiology 136
Current market dynamics 137
Key companies and leading brands in the Insomnia market 138
Issues affecting the global insomnia market 141
Key product launches and patent expiries through to 2016 143
Migraine 146
Key market insights 146
Disease definition 148
Epidemiology 149
Current market dynamics 151
Key companies and leading brands in the migraine market 154
Issues affecting the global migraine market 157
Key product launches and patent expiries through to 2016 163
Multiple Sclerosis 166
Key market insights 166
Market forecast summary 168
Disease definition 168
Epidemiology 169
Current market dynamics 170
Key companies and leading brands in the MS market 173
Environmental issues affecting the seven major MS markets 174
Key product launches and patent expiries through to 2016 178
Parkinson's disease 181
Key market insights 181
Market forecast summary 183
Disease definition 183
Epidemiology 184
Current market dynamics 186
Unmet needs in Parkinson's disease 187
Key product launches and patent expiries through to 2016 189
Other orphan neurological disorders 191
Amyotrophic lateral sclerosis (ALS/Motor neuron disease) 191
Huntington's disease 195
CHAPTER 5 PAIN 200
Market dynamics 202
Pain market size and structure 202
5EU is the key historical pain sector growth market 202
Key indication market dynamics 203
Commercial viability of key pain indications in 2015 204
Market dynamics and prevalence through to 2015 206
Historical sales dynamics of the three key pain indications over the period 2003-06 208
Company analysis 211
Pain drugs definition 211
Top five pain drug companies' comparative marketed and pipeline portfolio potential 212
Historical performance and top-line dynamics of the leading pain drug companies of 2007 214
Analysis of the top five pain drug companies of 2007 217
Star performer in the pain drug market 229
Major sector loser in the pain drug market 229
Brand analysis 230
Generic nature of pain sector sees leading brands being less dominant over market 230
Key non-traditional analgesics used in pain 231
Anticonvulsants for pain - Pregabalin and gabapentin gain significant revenues from neuropathic pain 232
Antidepressants for pain - Neuropathic pain an important revenue generator for Lilly's Cymbalta 233
Key disease-specific insight 234
Breakthrough pain 234
Key market insights 234
Market forecast summary 235
Disease definition 235
Epidemiology 236
Unmet needs in breakthrough pain 237
Fibromyalgia 237
Key market insights 237
Market forecast summary 238
Disease definition 239
Epidemiology 239
Current treatment approaches for fibromyalgia 240
Unmet needs in fibromyalgia 241
Neuropathic pain 242
Key market insights 242
Market forecast summary 243
Disease definition 243
Epidemiology 244
Current market dynamics 248
Current treatment approaches for neuropathic pain 249
Unmet needs in neuropathic pain 252
Traditional analgesic class dynamics 252
Opioids 252
Key market insights 253
Market forecast summary 253
Current market dynamics 254
Key product launches and patent expiries through to 2016 255
NSAIDs 258
Current market dynamics 258
Key brands in the NSAID market 262
CHAPTER 6 PSYCHIATRY 264
Market dynamics 266
Psychiatry market size and structure 266
US psychiatry sales dwarf that from the 5EU and Japan 266
Key indication market dynamics 267
Commercial viability of key psychiatric indications in 2015 268
Market dynamics and prevalence through to 2015 270
Historical sales dynamics of key psychiatric indications over the period 2003-06 273
Company analysis 276
Psychiatric drugs definition 276
Top five psychiatric drug companies' comparative marketed and pipeline portfolio potential 277
Historical performance and top-line dynamics of the leading psychiatric drug companies of 2008 279
Analysis of the top five psychiatric drug companies of 2007 282
Star performers within the psychiatric drug market - Teva and Reckitt Benckiser 297
Major psychiatric drug sector losers - Pfizer and GSK suffer after key antidepressants go generic 299
Brand analysis 301
Atypical antipsychotics and antidepressants fill nine of the top 10 places 301
Key non-traditional psychiatric drugs used in psychiatry 302
Anticonvulsants are regularly used to treat bipolar maintenance 303
Key disease-specific insight 304
Anxiety 304
Key market insights 304
Market forecast summary 304
Disease definition 305
Epidemiology 307
Current market dynamics 308
Unmet needs in Anxiety 309
ADHD 310
Key market insights 310
Market forecast summary 312
Disease definition 312
Epidemiology 313
Current market dynamics 316
Issues affecting the global ADHD market 318
Key product launches and patent expiries through to 2017 325
Bipolar disorder 328
Key market insights 328
Market forecast summary 329
Disease definition 330
Epidemiology 335
Current market dynamics 335
Unmet needs in bipolar disorder 338
Depression (Manic depressive disorder) 339
Key market insights 339
Market forecast summary 340
Disease definition 341
Epidemiology 342
Current market dynamics 343
Timeline of key events in the depression disease market 345
Issues affecting the global depression market 347
Key product launches and patent expiries through to 2016 351
Nicotine dependence 354
Key market insights 354
Market forecast summary 355
Disease definition 355
Epidemiology 357
Current market dynamics 358
Unmet needs in nicotine dependence 361
Schizophrenia 362
Key market insights 362
Market forecast summary 362
Disease definition 363
Epidemiology 364
Current market dynamics 364
Unmet needs in schizophrenia 365
BIBLIOGRAPHY 367
Literature 367
Websites 381
Datamonitor sources 389
APPENDIX A 392
International Classification of Diseases 392
Disease of the nervous system (neurology) 392
Mental and behavioral disorders (Psychiatry) 392
Estimated 2007 sales revenue 393
Top five sector drug companies' comparative marketed and pipeline portfolio potential methodology 393
Marketed potential 393
Pipeline potential 394
ATC classes included in 'others' to define the migraine market 395
ICD-10 codes used to define neuropathic pain market 396
APPENDIX B 398
Report methodology 398
About Datamonitor 398
About Datamonitor Healthcare 398
About the CNS analysis team 399
Disclaimer 400
List of Tables
Table 1: Key dynamics - Nervous system versus other therapeutic sectors, 7MM, 2004-07 17
Table 2: Central nervous system sector dynamic comparison - key volume and value metrics, 7MM, 2004-07 22
Table 3: Central nervous system regional dynamic comparison - key volume and value metrics, 7MM, 2004-07 27
Table 4: Commercial viability of the three CNS market sectors in 2015 29
Table 5: Market attractiveness - brand, company and generic dominance of the three CNS sectors, 7MM, 2007 32
Table 6: Top 10 selling CNS brands across the 7MM, 2007 38
Table 7: Top 10 CNS companies by CNS drug revenues across the 7MM, 2007 55
Table 8: Sector rankings of the top 10 CNS companies in 2007 56
Table 9: Other leading CNS companies according to forecast revenues, 2006-2012 65
Table 10: Commercial viability of key neurological indications in 2015 72
Table 11: Top 20 neurological drug companies by 2007 seven major market revenues, 2004-07 81
Table 12: Top five neurological drug companies in the 7MM by revenue versus the rest of the market, 2004-07 85
Table 13: Top five neurological drug companies by 7MM revenue versus rest of market, 2004-07 86
Table 14: GSK's neurological drug portfolio overview, 2004-07 88
Table 15: GSK's late-stage neurology pipeline, 2004-07 89
Table 16: J&J's neurological drug portfolio overview, 2004-07 91
Table 17: J&J's late-stage neurology pipeline, 2008 91
Table 18: Pfizer's neurological drug portfolio overview, 2004-07 92
Table 19: Pfizer's late-stage neurology pipeline, 2008 93
Table 20: Eisai's neurological drug portfolio overview, 2004-07 94
Table 21: Eisai's late-stage neurology pipeline, 2008 95
Table 22: Sanofi-Aventis's neurological drug portfolio overview, 2004-07 96
Table 23: Sanofi-Aventis's late-stage neurology pipeline, 2008 97
Table 24: Star performing neurological drug companies in the 7MM, 2004-07 98
Table 25: Top 10 neurological brands in the 7MM by revenue, 2004-07 101
Table 26: Population size and prevalence rate of Alzheimer's disease across the 7MM, 2008 106
Table 27: Summary of key environmental issues in the AD market across the 7MM, 2008 110
Table 28: Estimated launch dates for new Alzheimer's disease drugs in the 7MM, 2008-2017 114
Table 29: Patent expiry dates for the key approved Alzheimer's disease brands in the 7MM, 2008-2017 114
Table 30: Prevalence of epilepsy across the 7MM, 2008 118
Table 31: Key players in the epilepsy market, 2007 125
Table 32: Summary of environmental issues in the epilepsy market across the 7MM, 2008 128
Table 33: Estimated launch dates for new epilepsy drugs in the 7MM, 2007-2016 132
Table 34: Patent expiry dates for the key approved epilepsy brands in the 7MM, 2007-2016 133
Table 35: Diagnosed prevalence of insomnia in the 7MM, 2008 136
Table 36: Performance of the US, 5EU and Japan insomnia markets, 2005-06 137
Table 37: Key players in the insomnia market, 2007 139
Table 38: Summary of environmental issues in the seven major insomnia markets, 2007 141
Table 39: Estimated launch dates for new insomnia drugs in the 7MM, 2008-2016 145
Table 40: Dates of key patent expiries in the insomnia market across the 7MM, 2007-2016 145
Table 41: Prevalence of migraine across the 7MM, 2008 150
Table 42: Migraine population across the 7MM, 2008 151
Table 43: Key players in the migraine market, 2007 154
Table 44: Summary of environmental issues in the migraine market across the 7MM, 2007 157
Table 45: Datamonitor's estimated launch dates for migraine products in the 7MM, 2008-2016 165
Table 46: Key patent expiries of migraine brands across the 7MM, 2008-2016 166
Table 47: Prevalence of multiple sclerosis across the 7MM, 2008 170
Table 48: Key players in the multiple sclerosis market, 2007 174
Table 49: Summary of environmental issues in the multiple sclerosis market across the 7MM, 2007 175
Table 50: Datamonitor's estimated launch dates for MS products in the 7MM, 2008-2016 180
Table 51: Patent expiry dates for the approved multiple sclerosis disease-modifiers in the 7MM, 2008-2016 180
Table 52: Prevalence of PD across the 7MM, 2008 184
Table 53: Datamonitor's estimated launch dates for Parkinson's disease products in the 7MM, 2008-2016 190
Table 54: Key patent expiries of Parkinson's disease brands across the 7MM, 2008-2016 190
Table 55: Prevalence estimates of ALS across the 7MM, 2008 193
Table 56: HD base scenario prevalence and patient population in the 6MM, 2008 197
Table 57: Commercial viability of key pain indications in 2015 205
Table 58: Top 20 pain drug companies by 7MM revenue, 2004-07 211
Table 59: Top five pain drug companies in the by revenues versus the rest of the market, 2004-07 215
Table 60: Top five pain drug companies by 7MM revenues versus rest of market, 2004-07 215
Table 61: Pfizer's pain drug portfolio overview, 2004-07 217
Table 62: Pfizer's late-stage pain pipeline, 2008 219
Table 63: J&J's pain drug portfolio overview, 2004-07 220
Table 64: J&J's late-stage pain pipeline, 2008 221
Table 65: Mundi's pain drug portfolio overview, 2004-07 222
Table 66: Mundi's late-stage pain pipeline, 2008 223
Table 67: Endo's pain drug portfolio overview, 2004-07 225
Table 68: Endo's late-stage pain pipeline, 2008 226
Table 69: Teva's pain drug portfolio overview, 2004-07 227
Table 70: Star performing pain drug company in the 7MM, 2004-07 229
Table 71: Major pain drug sector company loser in the 7MM, 2004-07 230
Table 72: Top 10 pain brands by 7MM revenues, 2004-07 231
Table 73: Prevalence of fibromyalgia across the 7MM, 2008 240
Table 74: The diabetic neuropathic pain patient populations across the 7MM, 2008 246
Table 75: The HIV neuropathic pain patient population across the 7MM, 2008 247
Table 76: The post herpetic neuralgia patient population across the 7MM, 2008 248
Table 77: Estimated launch dates for new opioid drugs in the US and 5EU, 2008-2012 257
Table 78: Estimated launch dates for new opioid drugs in the Japan, 2008-2012 258
Table 79: Pivotal patent expiries for key marketed opioid drugs in the US and 5EU, 2008-2017 258
Table 80: Commercial viability of key psychiatry indications, 2015 268
Table 81: Top 20 psychiatric drug companies by 2007 seven major market revenues 276
Table 82: Top five psychiatric drug companies 7MM revenues versus the rest of the market, 2004-07 280
Table 83: Top five psychiatry drug companies by 2007 seven major market revenues versus rest of market 281
Table 84: Lilly's psychiatric drug portfolio overview, 2004-07 283
Table 85: Lilly's late-stage psychiatry pipeline, 2008 284
Table 86: J&J's psychiatric drug portfolio overview, 2004-07 286
Table 87: J&J's late-stage psychiatry pipeline, 2008 288
Table 88: AstraZeneca's psychiatric drug portfolio overview, 2004-07 290
Table 89: AstraZeneca's late-stage psychiatry pipeline, 2008 291
Table 90: Wyeth's psychiatric drug portfolio overview, 2004-07 293
Table 91: Wyeth's late-stage psychiatry pipeline, 2008 294
Table 92: Forest's psychiatric drug portfolio overview, 2004-07 296
Table 93: Star performing psychiatric drug companies in the 7MM, 2004-07 298
Table 94: Top 10 psychiatric brands by 7MMrevenues, 2004-07 301
Table 95: ICD-10 classification codes for anxiety disorders 306
Table 96: DSM-IV classification codes for anxiety disorders 307
Table 97: Prevalence rate of subcategories of anxiety disorder in the general population across the 7MM 308
Table 98: Results of epidemiology studies of ADHD across the 7MM 314
Table 99: Prevalence of ADHD in the 7MM, 2008 316
Table 100: Performance of the seven major ADHD markets, 2006-07e 318
Table 101: Summary of environmental issues in the ADHD market across the 7MM, 2008 319
Table 102: Datamonitor's forecast launch dates for key ADHD pipeline products in the 7MM, 2008-2017 327
Table 103: Key patent expiries for key marketed drugs in the US and 5EU, 2008-2017 328
Table 104: Diagnostic criteria for bipolar I disorders 333
Table 105: Diagnostic criteria for other types of bipolar disorders 334
Table 106: Prevalence data overview of bipolar disorder in the US, Canada and Switzerland, 2008 335
Table 107: Prevalence rate and population size for MDD across the 7MM, 2008 343
Table 108: Summary of environmental issues in the seven major MDD markets, 2007 347
Table 109: Datamonitor's forecast launch dates for key depression pipeline products in the US and 5EU, 2008-2016 352
Table 110: Datamonitor's forecast launch dates for key depression pipeline products in Japan, 2008-2016 353
Table 111: Key depression drugs forecast to face generic competition during the forecast period, 2007-2016 353
Table 112: DSM-IV criteria for nicotine dependence 356
Table 113: Prevalence of nicotine dependence in the 7MM, 2008 358
Table 114: Sales, growth and market share of Zyban and Chantix, 2005-06 360
Table 115: Key OTC nicotine replacement products, 2008 361
Table 116: Other ATC classes included for migraine market definition 395
Table 117: Neuropathic pain market definition by ICD-10 codes 396
List of Figures
Figure 1: Key dynamics - Nervous system versus other key therapeutic sectors, 7MM, 2004-07 19
Figure 2: Central nervous system market sales value split by sector, 2004-07 21
Figure 3: Central nervous system overview - key value and volume sales dynamics by sector, 7MM, 2004-07 24
Figure 4: Central nervous system market sales volume and sales value split by region, 2004-07 26
Figure 5: Market dynamics of key CNS indications, 2007-2015 31
Figure 6: CNS overview - market attractiveness by sector, 7MM, 2007 33
Figure 7: Comparative concentration of product sales in the neurology, pain and psychiatry markets - cumulative market share of top selling products in the 7MM, 2007 34
Figure 8: Comparative concentration of company sales in the neurology, pain and psychiatry markets - cumulative market share of top companies in the 7MM, 2007 35
Figure 9: CNS sector branded versus generic share as a proportion of 2007 sector sales revenues 36
Figure 10: CNS sector branded share as a proportion of sector sales revenues, 2004-07 37
Figure 11: Leading brand sales versus rest of market, 7MM, 2007 39
Figure 12: Seven major market CNS market sales value comparison by ATC3 class, 2006-2007 41
Figure 13: N3A-anticonvulsant ATC3 class sales value split by diagnosis, 2004-2007 42
Figure 14: Sales split of key anticonvulsant brands by diagnosis, 2007 43
Figure 15: N5A-antipsychotic ATC3 class sales value split by diagnosis, 2004-2007 44
Figure 16: Sales split of key antipsychotic brands by diagnosis, 2007 45
Figure 17: N6A-antidepressant ATC3 class sales value split by diagnosis, 2004-2007 47
Figure 18: Sales split of key antidepressant brands by diagnosis, 2007 48
Figure 19: Promotional spend in the US and 5EU CNS markets, 2004-06 50
Figure 20: Key dynamics of the top 10 highest promotional spend CNS ATC4 classes in the US, 2005-2006 51
Figure 21: Key dynamics of the top 10 highest promotional spend CNS ATC4 classes in the 5EU, 2005-2006 52
Figure 22: Key dynamics of the top 10 highest promotional spend CNS brands in the US, 2005-2006 53
Figure 23: Key dynamics of the top 10 highest promotional spend CNS brands in the 5EU, 2005-2006 54
Figure 24: Top 10 CNS companies' portfolio sector bias across the seven major market neurological, pain and psychiatric drug sectors, 2007 58
Figure 25: Neurology market sales value split by region, 2004-07 69
Figure 26: Neurology market sales volume split by region, 2004-07 70
Figure 27: Market dynamics and prevalence of key neurological indications, 2007-2015 74
Figure 28: Seven major market sales volume dynamics of the key neurology indications, 2003-06 76
Figure 29: Seven major market sales value dynamics of the key neurology indications, 2003-06 78
Figure 30: Regional variations in volume and value sales of key neurology indications, 2006 80
Figure 31: Comparative potential of the top five neurological drug companies' marketed and late-stage pipeline portfolios, 2008 83
Figure 32: Top five neurological drug companies 7MM revenue versus rest of market, 2004-07 87
Figure 33: Top 10 neurological brands in the 7MM by sales revenue, 2007 102
Figure 34: Datamonitor's base scenario Alzheimer's disease market forecast across the 7MM, 2007-2017 105
Figure 35: Overview of Datamonitor's AD population size methodology, 2008 107
Figure 36: AD-specific sales revenue, 7MM, 2003-07 108
Figure 37: AD-specific sales revenue ($ billions) by region, 2004-07 109
Figure 38: Forecast AD population, 2005-2050 110
Figure 39: Ageing population across 7MM, 2005-2050 111
Figure 40: Impact of each key event on the AD market across the seven major markets, 2008-2017 113
Figure 41: Datamonitor's epilepsy market forecast across the 7MM, 2007-2016 116
Figure 42: Incidence of epilepsy in different age groups 119
Figure 43: Epilepsy market value across the 7MM ($ billions), 2003-06 120
Figure 44: Sales volume (SUs billions) and value ($ billions) of first- versus second-generation anticonvulsants, 2003-06 121
Figure 45: Performance of the nine key epilepsy therapies ($m), 2005-06 122
Figure 46: Timeline: launch dates and patent expiries impacting the epilepsy market, 1995-2007 124
Figure 47: Impact of key events on the 7MM epilepsy market, 2007-2016 131
Figure 48: Datamonitor's insomnia market forecast across the 7MM, 2007-2016 135
Figure 49: Performance of the key insomnia therapies, 2005-06 138
Figure 50: Key drug launches and patent expiries in the insomnia market 1992-2006 139
Figure 51: Population aged over 65 years in the 7MM, 2007-2017 142
Figure 52: Key events impacting the insomnia market, 2007-2016 144
Figure 53: Datamonitor's migraine market forecast across the 7MM, 2007-2016 148
Figure 54: Migraine-specific sales revenue across the 7MM ($ billions), 2003-06 152
Figure 55: Performance of the nine key migraine therapies across the 7MM ($m), 2005-06 153
Figure 56: Migraine-specific sales in the 7MM for the four leading migraine prophylaxis drug classes ($m), 2003-06 158
Figure 57: Migraine-specific standard units prescribed in the 7MM for the four leading migraine prophylaxis drug classes, 2003-06 159
Figure 58: Total Topamax brand sales ($m) by indication in the US, 2003-06 160
Figure 59: Generic sumatriptan's impact in the German, Spanish and UK migraine markets ($m and SUs), 2006 162
Figure 60: Forecasted impact of Imitrex and Topamax patent expiry on the US migraine market ($ billion), 2006-2016 163
Figure 61: Key events impacting the migraine market, 2007-2016 164
Figure 62: Datamonitor's multiple sclerosis market forecast across the 7MM, 2007-2016 168
Figure 63: World distribution of multiple sclerosis 169
Figure 64: Multiple sclerosis market value across the 7MM ($ billions), 2003-06 171
Figure 65: Performance of the six disease-modifying multiple sclerosis therapies , 2005-06 172
Figure 66: Timeline: launch dates of disease-modifying therapies for treatment of multiple sclerosis, 1993-2006 173
Figure 67: Key events impacting the multiple sclerosis market, 2007-2016 179
Figure 68: Datamonitor's Parkinson's disease market forecast across the 7MM, 2007-2016 183
Figure 69: Age at diagnosis for each stage of PD, 2007 185
Figure 70: Parkinson's disease-specific sales revenue across the 7MM ($ billions), 2003-06 186
Figure 71: Performance of the seven key Parkinson's disease therapies across the 7MM ($m), 2005-06 187
Figure 72: Key unmet needs in Parkinson's disease, 2007 188
Figure 73: Key events impacting the Parkinson's disease market 2007-2016 189
Figure 74: Total ALS market sales revenue ($m), 2003-06 194
Figure 75: Key unmet needs in ALS treatment 195
Figure 76: Total sales revenue of the six major HD markets by drug class, 2003-06 198
Figure 77: Unmet needs in HD treatment, 2007 199
Figure 78: Pain market sales value split by region, 2004-07 202
Figure 79: Pain market sales volume split by region, 2004-07 203
Figure 80: Market dynamics and prevalence of key pain indications, 2007-2015 207
Figure 81: Seven major market sales volume dynamics of the key pain indications, 2003-06 209
Figure 82: Seven major market sales value dynamics of the key pain indications, 2003-06 210
Figure 83: Comparative potential of the top five pain drug companies' marketed and late-stage pipeline portfolios, 2008 213
Figure 84: Top five pain drug companies by 7MM revenues versus rest of market, 2004-07 216
Figure 85: Key neurological drugs used for pain indications, 2007 232
Figure 86: Cymbalta total brand sales breakdown by sector, 2007 233
Figure 87: Datamonitor's breakthrough pain market forecast across the 7MM, 2006-2016 235
Figure 88: US and 5EU fibromyalgia market ($m), 2006-2016 238
Figure 89: Datamonitor's neuropathic pain market forecast across the 7MM, 2007-2016 243
Figure 90: Neuropathic pain-specific sales revenue across the 7MM ($ billions), 2003-06 249
Figure 91: Key unmet needs in neuropathic pain, 2008 252
Figure 92: Datamonitor's opioid market forecast across the 7MM, 2007-2017 254
Figure 93: Opioid sales revenue (as a percentage of total 2004 sales) across the 7MM, 2004-07 255
Figure 94: Impact of each key event on the opioid market across the 7MM, 2007-12 256
Figure 95: NSAID sales revenue across the 7MM ($ billions), 2003-07 259
Figure 96: NSAID sales volume across the 7MM (SU billions), 2003-07 260
Figure 97: Sales revenues of the M1A1 and M1A3 ATC classes across the 7MM ($ billions), 2003-07 261
Figure 98: Sales volume of the M1A1 and M1A3 ATC classes across the 7MM (SU billions), 2003-07 262
Figure 99: Performance of the key NSAID brands across the 7MM ($m), 2006-07 263
Figure 100: Psychiatry market sales value split by region, 2004-07 266
Figure 101: Psychiatry market sales volume split by region, 2004-07 267
Figure 102: Market dynamics and prevalence of key psychiatric indications, 2007-2015 271
Figure 103: Seven major market sales volume dynamics of the key psychiatric indications, 2003-06 273
Figure 104: Seven major market sales value dynamics of the key psychiatry indications, 2003-06 275
Figure 105: Comparative potential of the top five psychiatric drug companies' marketed and late-stage pipeline portfolios, 2008 278
Figure 106: Top five psychiatry drug companies by 7MM revenues versus rest of market, 2004-07 282
Figure 107: Performance of Pfizer's and GSK's psychiatry portfolios by 7MM revenues versus the top five and the rest of the market, 2004-07 299
Figure 108: Key neurological drugs used for psychiatric indications, 2007 303
Figure 109: Datamonitor's anxiety disorders market forecast across the 7MM, 2006-2015 305
Figure 110: Anxiety-specific sales revenue across the 7MM ($ billions), 2002-05 309
Figure 111: Reasons why patients receiving antidepressant therapy are non-compliant 310
Figure 112: Datamonitor's ADHD market forecast across the 7MM, 2007-2017 312
Figure 113: ADHD market value across the 7MM ($ billions), 2004-07 317
Figure 114: Sales revenue ($m) of ADHD drugs prescribed for pediatric, adolescent and adult patients, 2004-07 320
Figure 115: Growth of sales revenue ($m) of drugs prescribed for pediatric, adolescent and adult ADHD in the US, 2004-07 322
Figure 116: Impact of each key event on the ADHD market across the seven major markets, 2008-2017 326
Figure 117: Datamonitor's bipolar disorder market forecast across the 7MM, 2006-2015 330
Figure 118: Symptoms associated with the two primary phases of bipolar disorder 332
Figure 119: Bipolar-specific sales revenue across the 7MM ($ billions), 2002-05 336
Figure 120: Key unmet needs in bipolar disorder, 2006 339
Figure 121: Datamonitor's MDD market forecast across the 7MM, 2007-2016 341
Figure 122: MDD market value across the 7MM ($ billions), 2003-06 344
Figure 123: MDD-specific sales revenues across the 7MM by drug class, 2006 345
Figure 124: Key events impacting the MDD market, 1950-2007 346
Figure 125: Generic incursion on branded MDD-specific antidepressant sales in the US (SUs), 2003-2016 349
Figure 126: Key events impacting the MDD market, 2007-2016 351
Figure 127: Datamonitor's nicotine dependence market forecast across the 7MM, 2007-2016 355
Figure 128: Total sales of the key prescription nicotine dependence products by region ($m), 2003-06 359
Figure 129: Datamonitor's schizophrenia market forecast across the 7MM, 2006-2015 363
Figure 130: Schizophrenia-specific sales revenue across the 7MM ($ billions), 2002-05 365